/주식/SVRA
SVRA

SVRA

USD

Savara Inc. Common Stock

$4.130-0.110 (-2.594%)

실시간 가격

Healthcare
생명공학
미국

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$4.240

고가

$4.300

저가

$4.115

거래량

0.81M

기업 기본 정보

시가총액

831.4M

산업

생명공학

국가

United States

거래 통계

평균 거래량

1.53M

거래소

NMS

통화

USD

52주 범위

저가 $1.89현재가 $4.130고가 $4.505

관련 뉴스

PR Newswire

Savara Inc. (SVRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

The Law Offices of Frank R. Cruz announces that investors with losses related to Savara Inc. ("Savara" or the "Company") (NASDAQ: SVRA) have...

더 보기
Savara Inc. (SVRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
GlobeNewswire

SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $10,000 In Savara To Contact Him Directly To Discuss Their Options If you suffered losses

더 보기
SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara
PR Newswire

Shareholders that lost money on Savara Inc.(SVRA) should contact The Gross Law Firm about pending Class Action - SVRA

The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA). Shareholders who purchased shares of SVRA during the...

더 보기
Shareholders that lost money on Savara Inc.(SVRA) should contact The Gross Law Firm about pending Class Action - SVRA
PR Newswire

SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 2024 and May...

더 보기
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit
BusinessWire

Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M

Savara Inc. (NASDAQ:SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the closing of its previously announced underwritten public offering of 28,452,381 shares of

더 보기
Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M
PR Newswire

Levi & Korsinsky Reminds Savara Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 7, 2025 - SVRA

Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS...

GlobeNewswire

Savara Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – SVRA

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ:SVRA). Shareholders who purchased shares of SVRA during the class period listed are